Table 2.
Baseline Characteristics of Patients With NVAF Taking Oral Anticoagulants Before and After Propensity Score Weighting
| Patient Baseline Characteristics | ||||||||
|---|---|---|---|---|---|---|---|---|
| Before Propensity Score Weighting | After Propensity Score Weighting | |||||||
| Apixaban (n=5843) | Dabigatran (n=20 079) | Rivaroxaban (n=27 777) | Warfarin (n=19 375) | Apixaban | Dabigatran | Rivaroxaban | Warfarin | |
| Age, y | 76±10 | 75±10 | 75±10 | 71±13 | 76±10 | 76±10 | 76±10 | 76±10 |
| Female | 45% (2629) | 40% (8018) | 45% (12 403) | 42% (8154) | 45% | 45% | 45% | 46% |
| CHA2DS2‐VASc | 3.89±1.56 | 3.74±1.52 | 3.83±1.57 | 3.26±1.81 | 3.89±1.56 | 3.88±0.82 | 3.89±0.71 | 3.89±0.88 |
| HAS‐BLED | 2.96±1.12 | 2.83±1.08 | 2.91±1.10 | 2.64±1.29 | 2.96±1.12 | 2.96±0.59 | 2.96±0.51 | 2.97±0.61 |
| Chronic lung disease | 13% (780) | 12% (2323) | 14% (3816) | 13% (2494) | 13% | 13% | 14% | 14% |
| Chronic liver disease | 16% (929) | 14% (2831) | 16% (4421) | 16% (3048) | 16% | 16% | 16% | 16% |
| Chronic kidney disease | 29% (1671) | 20% (3922) | 24% (6786) | 24% (4702) | 29% | 28% | 28% | 29% |
| Congestive heart failure | 13% (735) | 11% (2172) | 13% (3582) | 14% (2699) | 13% | 12% | 13% | 13% |
| Hypertension | 87% (5055) | 84% (16 863) | 86% (23 766) | 78% (15 099) | 87% | 87% | 86% | 87% |
| Hyperlipidemia | 54% (3161) | 50% (10 033) | 53% (14 747) | 45% (8742) | 54% | 54% | 54% | 54% |
| Diabetes mellitus | 41% (2389) | 38% (7647) | 39% (10 752) | 36% (6948) | 41% | 41% | 41% | 40% |
| Previous stroke | 20% (1173) | 24% (4778) | 20% (5675) | 15% (2936) | 20% | 20% | 20% | 20% |
| Previous TIA | 3% (167) | 3% (573) | 2% (667) | 2% (344) | 3% | 3% | 3% | 3% |
| Ischemic heart disease | 13% (733) | 10% (1961) | 12% (3399) | 11% (2098) | 13% | 13% | 13% | 12% |
| Gout | 25% (1453) | 23% (4525) | 24% (6779) | 23% (4496) | 25% | 25% | 25% | 25% |
| Peripheral artery disease | 0% (4) | 0% (11) | 0% (19) | 0% (16) | 0% | 0% | 0% | 0% |
| Malignancy | 10% (555) | 8% (1687) | 9% (2518) | 8% (1581) | 10% | 9% | 9% | 10% |
| History of bleeding | 2% (113) | 2% (415) | 2% (644) | 2% (451) | 2% | 2% | 2% | 2% |
| Use of NSAIDs | 27% (1556) | 22% (4401) | 24% (6657) | 25% (4792) | 27% | 27% | 27% | 26% |
| Use of PPI | 11% (655) | 8% (1654) | 11% (2906) | 13% (2421) | 11% | 11% | 11% | 11% |
| Use of ACEI/ARB | 6% (329) | 28% (5631) | 19% (5179) | 28% (5383) | 6% | 6% | 6% | 6% |
| Use of H2 blocker | 31% (1810) | 29% (5772) | 29% (8175) | 32% (6200) | 31% | 31% | 31% | 32% |
| Use of amiodarone | 28% (1649) | 22% (4498) | 27% (7370) | 39% (7472) | 28% | 28% | 28% | 28% |
| Use of dronedarone | 5% (286) | 2% (372) | 5% (1281) | 2% (464) | 5% | 5% | 5% | 5% |
| Use of β‐blocker | 59% (3451) | 54% (10 839) | 57% (15 782) | 61% (11 824) | 59% | 59% | 59% | 59% |
| Use of diltiazem/verapamil | 25% (1432) | 23% (4565) | 24% (6779) | 27% (5293) | 25% | 24% | 24% | 24% |
| Use of digoxin | 20% (1149) | 24% (4832) | 23% (6248) | 30% (5882) | 20% | 20% | 20% | 20% |
| Use of statin | 4% (229) | 20% (4101) | 14% (3949) | 17% (3322) | 4% | 4% | 4% | 4% |
| PCI | 7% (415) | 5% (916) | 6% (1750) | 5% (1051) | 7% | 7% | 7% | 7% |
| CABG | 1% (31) | 0% (40) | 0% (104) | 1% (143) | 1% | 0% | 0% | 1% |
ACEI indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin II receptor antagonists; CABG, coronary artery bypass graft; CHA2DS2‐VASc, congestive heart failure, hypertension, age 75 years or older, diabetes mellitus, previous stroke/transient ischemic attack, vascular disease, age 65 to 74 years, female; HAS‐BLED, hypertension, abnormal renal or liver function, stroke, bleeding history, labile INR, age 65 years or older, and antiplatelet drug or alcohol use (labile INR could not be determined from claims and was excluded from our scoring); NSAIDs, nonsteroidal anti‐inflammatory drugs; NVAF; nonvalvular atrial fibrillation; PCI, percutaneous coronary intervention; PPI, proton pump inhibitor; and TIA, transient ischemic attack.